Literature DB >> 9068814

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

J L Tavares1, A Wangoo, P Dilworth, B Marshall, S Kotecha, R J Shaw.   

Abstract

Overexuberant production of tumour necrosis factor-alpha (TNF-alpha) by macrophages and other cells is thought to contribute to the development of permanent lung damage in many inflammatory conditions. There is a need for an agent, without the side-effects of corticosteroids, which can reduce the production of TNF-alpha by macrophages activated by disease. This study evaluated the effect of thalidomide on lipopolysaccharide (LPS)-induced TNF-alpha production by human alveolar macrophages obtained from patients with tuberculosis and a group of other diseases associated with macrophage activation. Alveolar macrophages obtained by bronchoalveolar lavage from 31 patients (tuberculosis = 12, sarcoidosis = 3, lung cancer = 5, chronic bronchitis = 5, pneumonia = 6) were stimulated with LPS alone or LPS in combination with either thalidomide or dexamethasone. Cell-associated TNF-alpha, as measured by immunochemistry, and TNF-alpha released by macrophages, as assessed by ELISA, were markedly increased when cells were incubated with LPS (P < 0.05), and both were decreased following addition of thalidomide (P < 0.05) or dexamethasone (P < 0.05) to amounts similar to those observed when macrophages were incubated with medium alone. Similarly, TNF-alpha mRNA as measured by in situ hybridization was increased following incubation with LPS (P < 0.05), but this increase was prevented by addition of thalidomide (P < 0.05) or dexamethasone (P < 0.05). The ability of thalidomide to reduce LPS-induced TNF-alpha production by alveolar macrophages was the same when cells from patients with tuberculosis (a disease associated with TNF-alpha production) and cells from patients with the other conditions were compared. The ability of thalidomide to reduce TNF-alpha production by human alveolar macrophages from patients with active lung disease suggests that thalidomide and its analogues may have potential as drugs to reduce TNF-alpha production in disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9068814     DOI: 10.1016/s0954-6111(97)90134-7

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

1.  Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS).

Authors:  J Freysdottir; S Lau; F Fortune
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 2.  Potential immunotherapies for sarcoidosis.

Authors:  Van Le; Elliott D Crouser
Journal:  Expert Opin Biol Ther       Date:  2018-01-17       Impact factor: 4.388

3.  Tumor Necrosis Factor-α-Mediated Metaplastic Inhibition of LTP Is Constitutively Engaged in an Alzheimer's Disease Model.

Authors:  Anurag Singh; Owen D Jones; Bruce G Mockett; Shane M Ohline; Wickliffe C Abraham
Journal:  J Neurosci       Date:  2019-09-30       Impact factor: 6.167

Review 4.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 5.  [Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review].

Authors:  Carolin Nestle-Krämling; Edwin Bölke; Wilfried Budach; Matthias Peiper; Dieter Niederacher; Wolfgang Janni; Claus Ferdinand Eisenberger; Wolfram Trudo Knoefel; Axel Scherer; Stephan Ernst Baldus; Guido Lammering; Peter Arne Gerber; Christiane Matuschek
Journal:  Strahlenther Onkol       Date:  2011-08-16       Impact factor: 3.621

6.  Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-α and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line.

Authors:  Erian H Girgis; John P Mahoney; Rafaat H Khalil; Magdi R Soliman
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

Review 7.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

Review 9.  Dendritic cells in the pathogenesis of sarcoidosis.

Authors:  Lisa C Zaba; Gideon P Smith; Miguel Sanchez; Stephen D Prystowsky
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-16       Impact factor: 6.914

10.  The treatment of advanced renal cell cancer with high-dose oral thalidomide.

Authors:  J Stebbing; C Benson; T Eisen; L Pyle; K Smalley; H Bridle; I Mak; F Sapunar; R Ahern; M E Gore
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.